Grants and Contributions:
Title:
Identification and pre-clinical evaluation of peptide-based targeted alpha therapeutics (TATs) for the treatment of solid tumors
Agreement Number:
954353
Agreement Value:
$999,900.00
Agreement Date:
Jul 1, 2020 - Dec 29, 2023
Description:
This project is focused on the discovery and pre-clinical development of targeted alpha therapeutics using camelid-based constructs for the treatment of solid tumors with high unmet medical need.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Hamilton, Ontario, CA L8P 0A6
Reference Number:
172-2020-2021-Q2-954353
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
823021795
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 273 days. The total amended value is 249,900 dollars.
Amendment Date
Oct 17, 2022
Recipient's Legal Name:
Fusion Pharmaceuticals Inc.
Federal Riding Name:
Hamilton Centre
Federal Riding Number:
35035
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
54171
Amendments: